Literature DB >> 10809406

Effects of apomorphine on visual functions in Parkinson's disease.

T Büttner1, T Müller, W Kuhn.   

Abstract

The effect of apomorphine on visual functions in Parkinson's disease (PD) was evaluated by use of a static contrast sensitivity test (VCTS charts), a colour discrimination test (Farnsworth-Munsell 100 Hue test) and the examination of achromatic and chromatic contour perception. 31 patients (14 male, 17 female; mean age 60.9 +/- 9.2 years) with idiopathic PD were tested before and after an individual dosage of subcutaneously applied apomorphine showing a significant effect on motor function during the whole experiment. The achromatic spatial contrast sensitivity improved significantly after apomorphine injection with respect to all spatial frequencies. The improvement of colour discrimination after apomorphine application was minimal and not statistically significant. The small advantage of apomorphine with respect to colour discrimination may be explained by negative cognitive side-effects of apomorphine interfering with the test performance. The achromatic contour perception before and after apomorphine injection was unaltered. The contour fusion latency for the green stimulus was shortened, the latency for the rest of the examined coloured stimuli was delayed (= normalized) after apomorphine application. We conclude that apomorphine may be used as a test-drug for the examination of the dopaminergic response of the visual system in patients with PD. The improvement of basal visual functions by dopaminergic stimulation with apomorphine underlines the role of dopamine deficiency for visual dysfunction in PD.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10809406     DOI: 10.1007/s007020050007

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  7 in total

1.  The effect of docosahexaenoic Acid on visual evoked potentials in a mouse model of Parkinson's disease: the role of cyclooxygenase-2 and nuclear factor kappa-B.

Authors:  Ozlem Ozsoy; Gamze Tanriover; Narin Derin; Nimet Uysal; Necdet Demir; Burcu Gemici; Ceren Kencebay; Piraye Yargicoglu; Aysel Agar; Mutay Aslan
Journal:  Neurotox Res       Date:  2011-01-14       Impact factor: 3.911

2.  D1 and D2 receptor-mediated dopaminergic modulation of visual responses in cat dorsal lateral geniculate nucleus.

Authors:  Yongqiang Zhao; Nicolas Kerscher; Ulf Eysel; Klaus Funke
Journal:  J Physiol       Date:  2002-02-15       Impact factor: 5.182

3.  Apomorphine-induced differences in cortical and striatal EEG and their glutamatergic mediation in 6-hydroxydopamine-treated rats.

Authors:  Vasily Vorobyov; Frank Sengpiel
Journal:  Exp Brain Res       Date:  2008-08-06       Impact factor: 1.972

Review 4.  Pharmacological Insights into the Use of Apomorphine in Parkinson's Disease: Clinical Relevance.

Authors:  Manon Auffret; Sophie Drapier; Marc Vérin
Journal:  Clin Drug Investig       Date:  2018-04       Impact factor: 2.859

5.  Visual symptoms in Parkinson's disease.

Authors:  R A Armstrong
Journal:  Parkinsons Dis       Date:  2011-05-25

6.  Contrast Acuity With Different Colors in Parkinson's Disease.

Authors:  Harsh V Gupta; Nan Zhang; Erika Driver-Dunckley; Shyamal H Mehta; Thomas G Beach; Charles H Adler
Journal:  Mov Disord Clin Pract       Date:  2019-09-06

Review 7.  Oculo-Visual Dysfunction in Parkinson's Disease.

Authors:  R A Armstrong
Journal:  J Parkinsons Dis       Date:  2015       Impact factor: 5.568

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.